[HTML][HTML] Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - erc.bioscientifica.com
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-related …, 2020 - pubmed.ncbi.nlm.nih.gov
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - hal.univ-smb.fr
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - hal-ciheam.iamm.fr
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
[PDF][PDF] Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht, L Leenhardt… - Endocrine-Related …, 2020 - svedyn.com
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine …, 2020 - hal.sorbonne-universite.fr
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
[PDF][PDF] Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - cnrs.hal.science
63 Abstract 64 The management of radioiodine refractory thyroid cancers (RAIR TC) is
challenging for the 65 clinician. Tyrosine kinase inhibitors classically prescribed in this …
challenging for the 65 clinician. Tyrosine kinase inhibitors classically prescribed in this …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - ephe.hal.science
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
Redifferentiation of radioiodine-refractory thyroid cancers.
C Buffet, J Wassermann, F Hecht… - Endocrine-related …, 2020 - europepmc.org
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht, L Leenhardt… - Endocrine-Related …, 2020 - hal.science
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …